Anti-CTLA4: Issues in Development and Regulatory Approval
November 2, 2008
Westin Gaslamp Quarter Hotel
San Diego, CA
Presentation Slides & Schedule
Slides for select presentations below have been provided by the corresponding speaker for your convenience.
Please click the
next to the speaker's name to log in to view presentations.
Sunday, November 2, 2008 |
10:30 am - 10:35 am |
Introduction
Ulrich Keilholz, MD - Charité CBF |
10:35 am - 10:45 am |
Review of Ipilmumab Development Program and Data
Jeffrey S. Weber, MD, PhD - H. Lee Moffitt Cancer Center and Research Institute
|
10:45 am - 10:55 am |
Review of Tremilmumab Development Program and Data
Antoni Ribas, MD - UCLA Medical Center |
10:55 am - 11:05 am |
Comparison of Development Plans of IL2 and CTLA4 Abs
Mario Sznol, MD - Yale University School of Medicine |
11:05 am - 11:15 am |
Evaluation of IL2/Anti-CTLA4 Type Activity Data
Steven Hirschfeld, MD, PhD - National Institute of Child Health and Human Development |
11:15 am - 11:20 am |
Introduction into the Panel and Audience Discussion
Michael B. Atkins, MD - Beth Israel Deaconess Medical Center
|
11:20 am - 11:59 am |
Panel Discussion / Audience Questions |
11:59 am - 12:00 pm |
Closing Remarks
Ulrich Keilholz, MD - Charité CBF
|
12:00 pm |
Adjourn |
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.